Investors are betting on China’s potential to feed the global pharmaceutical pipeline, putting a multi-billion-dollar price tag on a handful of stocks, even as the country struggles to close a huge R&D gap with the West.
U.S. regulators approved a new therapy for a type of lymphoma, which was developed by Gilead Sciences Inc.’s Kite Pharma.
Novo Nordisk will take aim at Eli Lilly in the growing diabetes market after an advisory panel to the U.S. FDA gave the green light to its semaglutide drug.
Ignyta updated results from its STARTRK-2 clinical trial of entrectinib in non-small cell lung cancer (NSCLC), causing company stock to jump about five percent before settling down.
Two weeks after securing more than $46 million in financing, Visterra struck a deal worth up to $1 billion with startup Vir Biotechnology.
Eli Lilly signed an R&D collaboration deal with CureVac that could total up to $1.8 billion to develop and commercialize up to five possible cancer vaccines.
The prices of injectable cancer drugs – even older medicines around since the 1990s – are increasing at a rate far higher than inflation, researchers report in the Journal of Clinical Oncology.
President Donald Trump Backed away from a bipartisan deal from two U.S. senators to stabilize Obamacare by restoring subsidies to health insurers, one day after signaling his support for the plan.
A U.S. judge’s ruling invalidating Allergan Plc’s patents on its blockbuster $1.5 billion dry-eye medicine Restasis has cast doubt on the company’s novel strategy to enlist a Native American tribe to help shield those patents from challenge by generic drugmakers, legal experts said.
Johnson & Johnson won the reversal of a $72 million verdict in favor of the family of a woman whose death from ovarian cancer they claimed stemmed from her use of the company’s talc-based products like Johnson’s Baby Powder.